Breaking News Instant updates and real-time market news.

IPCI

Intellipharmaceutics

$2.38

0.139 (6.20%)

, AZN

AstraZeneca

$32.29

0.03 (0.09%)

18:37
10/07/16
10/07
18:37
10/07/16
18:37

Intellipharmaceutics announces tentative FDA approval for generic Seroquel XR

Intellipharmaceutics (IPCI) announced that the Company received tentative approval from the U.S. FDA for the Company's abbreviated new drug application for quetiapine fumarate extended-release tablets in the 50, 150, 200, 300 and 400 mg strengths. The Company's tentatively-approved product is a generic equivalent for the corresponding strengths of the branded product Seroquel XR sold in the United States by Astra Zeneca (AZN). Pursuant to a settlement agreement between the Company and AstraZeneca dated July 30, 2012, the Company is permitted to launch its generic versions of the 50, 150, 200, 300 and 400 mg strengths of generic Seroquel XR, on November 1, 2016, subject to FDA final approval of the Company's ANDA for those strengths. Such FDA final approval is subject to a 180 day exclusivity period relating to a prior filer or filers of a generic equivalent of the branded product. To our knowledge, two companies have first-to-file status and may be in a position to launch on November 1, 2016, although we cannot be certain of that date. Our intent is to launch these strengths after FDA final approval following expiry of the other companies' exclusivity period(s). There are currently no generics of Seroquel XR available in the U.S. market as the product is still under Astra Zeneca's patent protection until November 1, 2017. There can be no assurance that the Company's quetiapine fumarate extended-release tablets in any of the 50, 150, 200, 300 and 400 mg strengths will receive final FDA approval, or if approved, that they will be successfully commercialized.

IPCI

Intellipharmaceutics

$2.38

0.139 (6.20%)

AZN

AstraZeneca

$32.29

0.03 (0.09%)

  • 07

    Oct

  • 20

    Oct

  • 16

    Nov

IPCI Intellipharmaceutics
$2.38

0.139 (6.20%)

10/04/16
BMUR
10/04/16
INITIATION
Target $8
BMUR
Buy
Intellipharmaceutics assumed with a Buy at Brean Capital
Brean Capital analyst Difei Yang assumed coverage of Intellipharmaceutics with a Buy rating and $8 price target.
AZN AstraZeneca
$32.29

0.03 (0.09%)

09/13/16
EXAN
09/13/16
DOWNGRADE
EXAN
Neutral
AstraZeneca downgraded to Neutral from Outperform at Exane BNP Paribas
09/23/16
PIPR
09/23/16
INITIATION
PIPR
Overweight
AstraZeneca initiated with an Overweight at Piper Jaffray
Piper Jaffray analyst Richard Purkiss started AstraZeneca with an Overweight rating and GBP 60 price target.
09/23/16
09/23/16
INITIATION

On The Fly: Top five analyst initiations
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. Morgan Stanley analyst Brian Nowak initiated Activision Blizzard (ATVI) and Electronic Arts (EA), both with Overweight ratings. The analyst is bullish on the digital gaming shift away from "units sold" to a business model based on users, engagement, and digital monetization. He sees digital in-game offerings resulting in recurring and growth user bases, increased per-game engagement, and further monetization opportunities. 2. AstraZeneca (AZN) and GlaxoSmithKline (GSK) both initiated with Overweight ratings by Piper Jaffray analyst Richard Purkiss. 3. Achillion (ACHN) initiated with an Outperform by Wedbush analyst Heather Behanna, who set a $13 price target on the shares. 4. Sysco (SYY) initiated with an Underweight at Barclays and $48 price target by analyst Karen Short. 5. Five Below (FIVE), Dollar Tree (DLTR) and Dollar General (DG) all initiated with Equal Weight ratings by Barclays analyst Karen Short. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
10/07/16
PIPR
10/07/16
NO CHANGE
PIPR
Neutral
Piper still sees Clovis' rucaparib getting broader indication than Lynparza
Piper Jaffray analyst Steven Breazzano said the rucaparib response rates in platinum resistant and platinum refractory patients of 25% and 0%, respectively, reported by Clovis Oncology (CLVS) are lower than some may have been expecting and "seemingly negative on the surface." However, he continues to believe rucaparib will be approved in BRCA patients who have received 2+ lines of therapy, which is an earlier and broader patient population than assigned to competitor AstraZeneca's (AZN) Lynparza, he tells investors. The ultimate market potential and key to success is the maintenance setting, for which TESARO's (TSRO) niraparib is still best-positioned, adds Breazzano, who keeps a Neutral rating on Clovis shares.

TODAY'S FREE FLY STORIES

15:15
03/01/17
03/01
15:15
03/01/17
15:15
General news
Treasury Closing Summary: »

Treasury Closing Summary:…

ILG

ILG

$18.88

-0.21 (-1.10%)

15:11
03/01/17
03/01
15:11
03/01/17
15:11
Options
Notable call spread in ILG after earnings were reported yesterday »

Notable call spread in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 14

    Mar

  • 15

    Mar

  • 16

    Mar

PRGX

PRGX Global

$6.25

0.45 (7.76%)

15:10
03/01/17
03/01
15:10
03/01/17
15:10
Upgrade
PRGX Global rating change  »

PRGX Global upgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

PDCE

PDC Energy

$67.59

-4.1 (-5.72%)

15:05
03/01/17
03/01
15:05
03/01/17
15:05
Upgrade
PDC Energy rating change  »

PDC Energy upgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Mar

  • 20

    Apr

  • 20

    Apr

JUNO

Juno Therapeutics

$24.04

0.64 (2.74%)

15:05
03/01/17
03/01
15:05
03/01/17
15:05
Options
Juno Therapeutics options imply 11.3% move in share price post-earnings, above median historical move »

Pre-earnings options…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 01

    Mar

  • 01

    Apr

SBGI

Sinclair Broadcast

$39.90

-0.05 (-0.13%)

15:01
03/01/17
03/01
15:01
03/01/17
15:01
Hot Stocks
Sinclair Broadcast acquires Tennis Media Company in up to $14M deal »

Sinclair Broadcast Group…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 06

    Mar

PRGX

PRGX Global

$6.25

0.45 (7.76%)

15:01
03/01/17
03/01
15:01
03/01/17
15:01
Upgrade
PRGX Global rating change  »

PRGX Global upgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TXT

Textron

$49.46

2.16 (4.57%)

15:01
03/01/17
03/01
15:01
03/01/17
15:01
Options
Bullish flow in Textron as shares rally »

Bullish flow in Textron…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 06

    Mar

NUS

Nu Skin

$49.41

-0.13 (-0.26%)

, EQY

Equity One

$31.20

-0.46 (-1.45%)

14:55
03/01/17
03/01
14:55
03/01/17
14:55
Hot Stocks
Breaking Hot Stocks news story on Nu Skin, Equity One »

Nu Skin to replace Equity…

NUS

Nu Skin

$49.41

-0.13 (-0.26%)

EQY

Equity One

$31.20

-0.46 (-1.45%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

REG

Regency Centers

$69.37

-0.98 (-1.39%)

, ENDP

Endo

$13.65

0.36 (2.71%)

14:55
03/01/17
03/01
14:55
03/01/17
14:55
Hot Stocks
Regency Centers to replace Endo in S&P 500 as of 3/2 open »

Regency Centers (REG) is…

REG

Regency Centers

$69.37

-0.98 (-1.39%)

ENDP

Endo

$13.65

0.36 (2.71%)

EQY

Equity One

$31.20

-0.46 (-1.45%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 13

    Mar

  • 14

    Mar

ENDP

Endo

$13.65

0.36 (2.71%)

, REG

Regency Centers

$69.37

-0.98 (-1.39%)

14:55
03/01/17
03/01
14:55
03/01/17
14:55
Hot Stocks
Breaking Hot Stocks news story on Endo, Regency Centers »

Endo to replace Regency…

ENDP

Endo

$13.65

0.36 (2.71%)

REG

Regency Centers

$69.37

-0.98 (-1.39%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 13

    Mar

  • 14

    Mar

XOP

SPDR Oil Exploration and Production Fund

$38.88

1.0201 (2.69%)

14:51
03/01/17
03/01
14:51
03/01/17
14:51
Options
Hefty put spread in SPDR Oil Exploration and Production ETF »

Hefty put spread in SPDR…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MNST

Monster Beverage

$41.44

-0.65 (-1.54%)

14:50
03/01/17
03/01
14:50
03/01/17
14:50
Options
Monster Beverage options imply 9.8% move in share price post-earnings, above median historical move »

Pre-earnings options…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

IPXL

Impax

$14.25

-0.4 (-2.73%)

14:45
03/01/17
03/01
14:45
03/01/17
14:45
Downgrade
Impax rating change  »

Impax downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 01

    Mar

  • 06

    Mar

  • 14

    Mar

14:45
03/01/17
03/01
14:45
03/01/17
14:45
General news
Market remains at record levels in afternoon trading »

Stocks remain sharply…

GD

General Dynamics

$192.22

2.41 (1.27%)

14:43
03/01/17
03/01
14:43
03/01/17
14:43
Hot Stocks
General Dynamics boosts dividend to 84c per share, adds 10M shares to buyback »

The board of directors of…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

P

Pandora

$12.26

-0.125 (-1.01%)

, SIRI

Sirius XM

$5.09

-0.09 (-1.74%)

14:41
03/01/17
03/01
14:41
03/01/17
14:41
Periodicals
Liberty Media: Pandora is 'great product,' 'way undermonetized,' Bloomberg says »

Sirius XM (SIRI) CEO…

P

Pandora

$12.26

-0.125 (-1.01%)

SIRI

Sirius XM

$5.09

-0.09 (-1.74%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 01

    Mar

  • 06

    Mar

  • 19

    Mar

  • 22

    Mar

  • 23

    Mar

GNW

Genworth

$4.14

0.0501 (1.22%)

14:41
03/01/17
03/01
14:41
03/01/17
14:41
Conference/Events
Genworth to host special shareholder meeting »

Special shareholder…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 07

    Mar

GD

General Dynamics

$192.08

2.27 (1.20%)

14:40
03/01/17
03/01
14:40
03/01/17
14:40
Hot Stocks
Breaking Hot Stocks news story on General Dynamics »

General Dynamics…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SPY

SPDR S&P 500 ETF Trust

$240.20

3.73 (1.58%)

, SPX

S&P 500

$2,399.94

36.3 (1.54%)

14:38
03/01/17
03/01
14:38
03/01/17
14:38
Technical Analysis
S&P 500 crosses 2400 for the first time »

The S&P 500 (SPX) has…

SPY

SPDR S&P 500 ETF Trust

$240.20

3.73 (1.58%)

SPX

S&P 500

$2,399.94

36.3 (1.54%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

KAR

KAR Auction

$45.02

0.2 (0.45%)

14:33
03/01/17
03/01
14:33
03/01/17
14:33
Hot Stocks
KAR Auction appoints Howse as Chief Commercial Officer »

KAR Auction Services…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 13

    Mar

  • 14

    Mar

  • 15

    Mar

APD

Air Products

$142.94

2.47 (1.76%)

, MPC

Marathon Petroleum

$51.23

1.63 (3.29%)

14:30
03/01/17
03/01
14:30
03/01/17
14:30
Hot Stocks
Air Products says wins additional Marathon Petroleum supply contract »

Air Products (APD)…

APD

Air Products

$142.94

2.47 (1.76%)

MPC

Marathon Petroleum

$51.23

1.63 (3.29%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Apr

CETX

Cemtrex

$3.54

-0.28 (-7.33%)

14:29
03/01/17
03/01
14:29
03/01/17
14:29
Hot Stocks
Cemtrex announces stock buyback of over 200K shares »

Cemtrex announced today…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MDCA

MDC Partners

$8.75

-0.1 (-1.13%)

14:27
03/01/17
03/01
14:27
03/01/17
14:27
Hot Stocks
MDC Partners received subpoena from Department of Justice »

MDC Partners disclosed in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 03

    Mar

  • 06

    Mar

BUD

AB InBev

$109.93

0.44 (0.40%)

, KR

Kroger

$32.09

0.285 (0.90%)

14:26
03/01/17
03/01
14:26
03/01/17
14:26
Earnings
Notable companies reporting before tomorrow's open »

Notable companies…

BUD

AB InBev

$109.93

0.44 (0.40%)

KR

Kroger

$32.09

0.285 (0.90%)

BURL

Burlington Stores

$87.24

-1.77 (-1.99%)

JOY

Joy Global

$28.20

0.005 (0.02%)

ANF

Abercrombie & Fitch

$11.25

-0.51 (-4.34%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 02

    Mar

  • 02

    Mar

  • 07

    Mar

  • 19

    Mar

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.